| Literature DB >> 11536076 |
X P Zhou1, K Woodford-Richens, R Lehtonen, K Kurose, M Aldred, H Hampel, V Launonen, S Virta, R Pilarski, R Salovaara, W F Bodmer, B A Conrad, M Dunlop, S V Hodgson, T Iwama, H Järvinen, I Kellokumpu, J C Kim, B Leggett, D Markie, J P Mecklin, K Neale, R Phillips, J Piris, P Rozen, R S Houlston, L A Aaltonen, I P Tomlinson, C Eng.
Abstract
Juvenile polyposis syndrome (JPS) is an inherited hamartomatous-polyposis syndrome with a risk for colon cancer. JPS is a clinical diagnosis by exclusion, and, before susceptibility genes were identified, JPS could easily be confused with other inherited hamartoma syndromes, such as Bannayan-Riley-Ruvalcaba syndrome (BRRS) and Cowden syndrome (CS). Germline mutations of MADH4 (SMAD4) have been described in a variable number of probands with JPS. A series of familial and isolated European probands without MADH4 mutations were analyzed for germline mutations in BMPR1A, a member of the transforming growth-factor beta-receptor superfamily, upstream from the SMAD pathway. Overall, 10 (38%) probands were found to have germline BMPR1A mutations, 8 of which resulted in truncated receptors and 2 of which resulted in missense alterations (C124R and C376Y). Almost all available component tumors from mutation-positive cases showed loss of heterozygosity (LOH) in the BMPR1A region, whereas those from mutation-negative cases did not. One proband with CS/CS-like phenotype was also found to have a germline BMPR1A missense mutation (A338D). Thus, germline BMPR1A mutations cause a significant proportion of cases of JPS and might define a small subset of cases of CS/BRRS with specific colonic phenotype.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11536076 PMCID: PMC1226057 DOI: 10.1086/323703
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.025